Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 7/20 | 0.74 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.74 |
| ▸ | TNF | P01375 | 2/20 | 0.48 |
| ▸ | IL1B | P01584 | 2/20 | 0.48 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.48 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 2/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.37 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.37 |
| ▸ | HTR3B | O95264 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.37 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30896328 | 1.00 | CRBN (0.74) | CRBNDDB1TNFIL1BIKZF1 | |
| SCHEMBL1962200 | 1.00 | CRBN (0.74) | CRBNDDB1TNFIL1BIKZF1 | |
| SCHEMBL4674905 | 1.00 | CRBN (0.74) | CRBNDDB1TNFIL1BIKZF1 | |
| SCHEMBL2049089 | 0.89 | DDB1 (0.74) | CRBNDDB1TNFIL1BIKZF1 | |
| SCHEMBL6179617 | 0.89 | DDB1 (0.74) | CRBNDDB1TNFIL1BIKZF1 | |
| SCHEMBL2049091 | 0.89 | DDB1 (0.74) | CRBNDDB1TNFIL1BIKZF1 | |
| SCHEMBL14533518 | 0.88 | CRBN (0.64) | CRBNDDB1TNFIL1BIKZF1 | |
| SCHEMBL8259914 | 0.87 | CRBN (0.57) | CRBNDDB1TNFIL1BIKZF1 | |
| SCHEMBL13699738 | 0.87 | DDB1 (0.57) | CRBNDDB1TNFIL1BIKZF1 | |
| SCHEMBL17169674 | 0.86 | CRBN (0.72) | CRBNDDB1IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 375 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160096818-A1 | SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNFALPHA LEVELS | CELGENE CORPORATION | 2016-04-07 | — | — | US | claimed |
| US-20140187584-A1 | Substituted 2-(2,6-Dioxopiperidin-3-yl)-phthalimides and -1-Oxoisoindolines and Method of Reducing TNFalpha Levels | CELGENE CORPORATION (US) | 2014-07-03 | — | — | US | claimed |
| US-20130030021-A1 | Substituted 2-(2,6-Dioxopiperidin-3-yl)-phthalimides and 1-Oxoisoindolines and Method of Reducing TNFalpha Levels | CELGENE CORPORATION (US) | 2013-01-31 | — | — | US | claimed |
| EP-2168958-A1 | Isoindole-Imide Compounds, Compositions And Uses Thereof | CELGENE CORPORATION (US) | 2010-03-31 | — | — | EP | claimed |
| EP-2070920-A1 | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing TNF alpha levels | CELGENE CORPORATION (US) | 2009-06-17 | — | — | EP | claimed |
| US-7459466-B2 | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing TNFα levels | CELGENE CORPORATION (US) | 2008-12-02 | — | — | US | claimed |
| EP-1486496-B1 | Substituted 2-(2,6-Dioxopiperidin-3-yl)-Phthalimides and method fo reducing TNF alpha levels | CELGENE CORP (US) | 2008-07-16 | — | — | EP | claimed |
| US-20080161360-A1 | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes | CELGENE CORPORATION | 2008-07-03 | — | — | US | claimed |
| EP-1848433-A2 | METHODS AND COMPOSITIONS USING 4-AMINO-2-(3-METHYL-2,6-DIOXOPIPERIDIN-3-YL)-ISOINDOLE-1-3-DIONE | CELGENE CORPORATION (US) | 2007-10-31 | — | — | EP | claimed |
| US-20060205787-A1 | Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1,3-dione | MULLER GEORGE W | 2006-09-14 | — | — | US | claimed |
| WO-2006081251-A2 | METHODS AND COMPOSITIONS USING 4-AMINO-2-(3-METHYL-2,6-DIOXOPIPERIDIN-3-YL)-ISOINDOLE-1-3-DIONE | CELGENE CORPORATION (US) | 2006-08-03 | — | — | WO | claimed |
| US-20050131024-A1 | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing TNFalpha levels | CELGENE CORPORATION | 2005-06-16 | — | — | US | claimed |
| EP-1363900-A1 | ISOINDOLE-IMIDE COMPOUNDS AS TNF-INHIBITORS | CELGENE CORPORATION (US) | 2003-11-26 | — | — | EP | claimed |
| US-20030144325-A1 | Isoindolines, method of use, and pharmaceutical compositions | MULLER GEORGE W (US) | 2003-07-31 | — | — | US | claimed |
| US-20030096841-A1 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION | 2003-05-22 | — | — | US | claimed |
| US-20020183360-A1 | Substituted 2-(2,6-dioxopiperidin-3-YL)-phthalimides and -1-oxoisoindolines and method of reducing TNFalpha levels | MULLER GEORGE W (US) | 2002-12-05 | — | — | US | claimed |
| WO-2002059106-A1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CELGENE CORPORATION (US) | 2002-08-01 | — | — | WO | claimed |
| US-20020045643-A1 | Isoindolines, method of use, and pharmaceutical compositions | MULLER GEORGE W (US) | 2002-04-18 | — | — | US | claimed |
| EP-0925294-A1 | SUBSTITUTED 2(2,6-DIOXOPIPERIDIN-3-YL)PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORPORATION (US) | 1999-06-30 | — | — | EP | claimed |
| WO-1998003502-A1 | SUBSTITUTED 2(2,6-DIOXOPIPERIDIN-3-YL)PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORPORATION (US) | 1998-01-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096818-A1 | SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNFALPHA LEVELS | TNF, NFKBIA, TRAF2 | CRBN 3501/4885DDB1 447/4885TNF 1/4885 |
| US-20030144325-A1 | Isoindolines, method of use, and pharmaceutical compositions | TNF, INA, VIP | CRBN 4462/4885DDB1 3090/4885TNF 1/4885 |
| US-20140187584-A1 | Substituted 2-(2,6-Dioxopiperidin-3-yl)-phthalimides and -1-Oxoisoindolines and Method of Reducing TNFalpha Levels | TNF, NFKBIA, TRAF2 | CRBN 3501/4885DDB1 447/4885TNF 1/4885 |
| US-20030096841-A1 | Isoindole-imide compounds, compositions, and uses thereof | TNF, IKZF3, IKZF1 | CRBN 1511/4885DDB1 3650/4885TNF 1/4885 |
| US-20080161360-A1 | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes | IL2, MCL1, MYD88 | CRBN 1257/4885DDB1 1332/4885TNF 466/4885 |
| US-20060205787-A1 | Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1,3-dione | HTR5A, IDO1, HTR3C | CRBN 1786/4885DDB1 2398/4885TNF 3851/4885 |
| US-20020183360-A1 | Substituted 2-(2,6-dioxopiperidin-3-YL)-phthalimides and -1-oxoisoindolines and method of reducing TNFalpha levels | TNF, TNFRSF1A, TRAF2 | CRBN 3437/4885DDB1 1125/4885TNF 1/4885 |
| US-20020045643-A1 | Isoindolines, method of use, and pharmaceutical compositions | TNF, OPRK1, OPRD1 | CRBN 4469/4885DDB1 3697/4885TNF 1/4885 |
| US-20130030021-A1 | Substituted 2-(2,6-Dioxopiperidin-3-yl)-phthalimides and 1-Oxoisoindolines and Method of Reducing TNFalpha Levels | TNF, NFKBIA, TRAF2 | CRBN 3601/4885DDB1 396/4885TNF 1/4885 |
| US-20050131024-A1 | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing TNFalpha levels | TNF, TNFRSF1A, IL1A | CRBN 3510/4885DDB1 1386/4885TNF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.